Phase 3 Recruiting NIH
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
+ 323 more sites in the U.S.
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Locations: - University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Fremont - Rideout Cancer Center — Marysville, California
- VA Palo Alto Health Care System — Palo Alto, California
+ 196 more sites in the U.S.
Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
+ 103 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Locations: - Research Site — Mobile, Alabama
- Research Site — Anchorage, Alaska
- Research Site — Phoenix, Arizona
+ 80 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares cetuxumab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer who are unable to receive cisplatin. Cetuximab is in a …
Sponsor: NRG Oncology
NCT ID: NCT07441681
Locations: - Tower Cancer Research Foundation — Beverly Hills, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California
+ 60 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizum…
Sponsor: Bicara Therapeutics
NCT ID: NCT06788990
Locations: - Site # 0137 — Birmingham, Alabama
- Site #0147 — Phoenix, Arizona
- Site #0107 — La Jolla, California
+ 47 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Locations: - Ironwood Cancer and Research Center — Chandler, Arizona
- University of Arizona Cancer Center — Tucson, Arizona
- Providence St Jude Medical Center — Fullerton, California
+ 44 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Sponsor: Merus B.V.
NCT ID: NCT06525220
Locations: - Site 164 — Mobile, Alabama
- Site 36 — La Jolla, California
- Site 27 — Los Angeles, California
+ 34 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Locations: - GSK Investigational Site — Jonesboro, Arkansas
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Solvang, California
+ 33 more sites in the U.S.
Phase 3 Recruiting Industry
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve,…
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT04892173
Locations: - University of Alabama at Birmingham — Birmingham, Alabama
- City of Hope — Duarte, California
- University of California at San Diego Moores Cancer Center — La Jolla, California
+ 23 more sites in the U.S.
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Locations: - Florida Cancer Specialists - South ( Site 7001) — Fort Myers, Florida
- Mount Sinai Braman Comprehensive Cancer Center ( Site 5043) — Miami Beach, Florida
- Mount Sinai Comprehensive Cancer Center ( Site 6000) — Miami Beach, Florida
+ 22 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ …
Sponsor: BioNTech SE
NCT ID: NCT04534205
Locations: - California Research Institute — Los Angeles, California
- UCLA Cancer Care — Los Angeles, California
- Stanford Cancer Institute — Palo Alto, California
+ 16 more sites in the U.S.